Wednesday, September 22, 2010
During routine in vitro fertilizaiton procedures, surplus embryos may be preserved by freezing or discarded. This raises the issue of what to do with embryos not suitable or desired for implantation. To date, implantation of embryos that have been biopsied using PGD, then frozen, has not lead to successful pregnancies. However, the technical challenges are being overcome.
Some chronic conditions can be very expensive to treat. The lifetime cost of treating a person with beta-thalassemia is several hundred thousand dollars. Should cost be a factor in deciding whether to pursue pre-implantation diagnosis? Should insurance companies be allowed to offer inducements to parents to pursue PGD if there is a family history or are they are seeking in vitro fertilization?
To what extent should the nature of the disease influence the availablility of pre-implantation diagnosis? Consider: persons homozygous for for cystic fibrois or Duchenne's Muscular Dystropy will develop the disease. Symptoms begin early and significantly reduce the quality of life, often leading to premature death. In contrast, individuals with an allele for Huntington's disease will not experience symptoms until later in life. Further, persons with a gene for breast or bowel cancer may not develop the disease at all. Preventative screenings for both cancers (mammograms and colonoscopies) are available. Who should decide: the government, voters, or should this be a private matter?
Subscribe to:
Posts (Atom)